Here’s what you need to know.
1. Vivelix paid Idera $15 million for rights to the drug. Idera is also eligible for IMO-9200 development, regulatory and sales milestones payments for up to $140 million.
2. Idera will develop back-up compounds to IMO-9200 at Vivelix’s expense. Idera is eligible for up to $52.5 million in royalties based on net sales of those back-up compounds.
3. According to a release, “IMO-9200 is an orally delivered synthetic oligonucleotide-based antagonist of toll-like receptor 7,8 and 9”
In preclinical studies, the drug has “demonstrated activity” when used with acute and chronic inflammation in the GI tract.
4. CEO of Vivelix Bill Forbes said he is excited to develop the “potentially life-changing therapy.”
More articles on gastroenterology/endoscopy:
Genetic Technologies, University of Melbourne collaborate on CRC risk assessment tool: 3 notes
Do financial incentives promote patient adherence to CRC screening? 5 study insights
GI leader to know: Dr. Carl Gessner of LeBauer HealthCare
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
